{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:08:22Z","timestamp":1788174502571,"version":"build-2803163510"},"reference-count":31,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Mosunetuzumab is approved as an intravenous (IV) formulation for relapsed\/refractory (R\/R) follicular lymphoma (FL) after \u2265\u20092 prior therapies. A subcutaneous (SC) formulation, aiming to improve patient safety and convenience, has been developed. We report the primary analysis of pharmacokinetics (PK), efficacy, and safety of mosunetuzumab SC (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u200994; median follow\u2010up: 26.1\u2009months) at the recommended Phase 2 dose (Cycle [C]1\u2009Day [D]1: 5\u2009mg; C1D8 and D15, and C2D1 onwards: 45\u2009mg) in patients with R\/R FL after \u2265\u20092 prior therapies, alongside data from a within\u2010study comparator cohort of mosunetuzumab IV in a similar patient population (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u200990; median follow\u2010up: 22.5\u2009months). The co\u2010primary PK endpoints (C\n                    <jats:sub>trough<\/jats:sub>\n                    and AUC) were met, demonstrating non\u2010inferior exposure of mosunetuzumab SC versus IV (observed C\n                    <jats:sub>trough[C3]<\/jats:sub>\n                    : geometric mean ratio [GMR] 1.39 [90% confidence interval (CI): 1.20\u20131.61]; AUC\n                    <jats:sub>0\u201384<\/jats:sub>\n                    : GMR 1.06 [90% CI: 0.92\u20131.21]). Mosunetuzumab SC efficacy was consistent with IV: overall response rate, 76.6% (95% CI: 66.7\u201384.7); complete response rate, 61.7% (95% CI: 51.1\u201371.5); median duration of complete response, 34.6\u2009months (95% CI: 20.7\u2013not evaluable [NE]); and median progression\u2010free survival, 23.7\u2009months (95% CI: 14.6\u2013NE). Mosunetuzumab SC demonstrated a favorable safety profile versus mosunetuzumab IV with a numerically lower rate (29.8% vs. 44.4%) and severity (grade \u2265\u20092: 9.6% vs. 18.9%) of cytokine release syndrome (CRS) events. Mosunetuzumab SC combines the benefits of short administration time, fixed\u2010duration treatment, outpatient accessibility, and low CRS rate, offering clinically meaningful improvements in patient convenience and safety.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Trial Registration:<\/jats:bold>\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.clinicaltrials.gov\">www.clinicaltrials.gov<\/jats:ext-link>\n                    : NCT02500407.\n                  <\/jats:p>","DOI":"10.1002\/ajh.70225","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T03:50:51Z","timestamp":1774065051000},"page":"986-997","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Fixed\u2010Duration Subcutaneous Mosunetuzumab in Relapsed\/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis"],"prefix":"10.1002","volume":"101","author":[{"given":"Nancy L.","family":"Bartlett","sequence":"first","affiliation":[{"name":"Siteman Cancer Center, Washington University School of Medicine  St. Louis Missouri USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie H.","family":"Sehn","sequence":"additional","affiliation":[{"name":"BC Cancer Centre for Lymphoid Cancer and the University of British Columbia  Vancouver British Columbia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarit","family":"Assouline","sequence":"additional","affiliation":[{"name":"Jewish General Hospital  Montreal Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratyush","family":"Giri","sequence":"additional","affiliation":[{"name":"Royal Adelaide Hospital  Adelaide Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kuruvilla","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Schuster","sequence":"additional","affiliation":[{"name":"Lymphoma Program, Abramson Cancer Center, University of Pennsylvania  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung\u2010Soo","family":"Yoon","sequence":"additional","affiliation":[{"name":"Seoul National University Hospital  Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Fay","sequence":"additional","affiliation":[{"name":"St Vincent's Hospital and Royal North Shore Hospital  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Hess","sequence":"additional","affiliation":[{"name":"University Cancer Center Mainz, University Medical School of the Johannes Gutenberg\u2010University  Mainz Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[{"name":"Ludwig\u2010Maximilians\u2010University Hospital Munich  Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5834-9510","authenticated-orcid":false,"given":"Norma C.","family":"Gutierrez","sequence":"additional","affiliation":[{"name":"University Hospital of Salamanca, IBSAL, Cancer Research Center\u2010IBMCC (USAL\u2010CSIC), CIBERONC  Salamanca Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Cybulski","sequence":"additional","affiliation":[{"name":"Genentech, Inc.  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fidelis","family":"Sabalvaro","sequence":"additional","affiliation":[{"name":"Genentech, Inc.  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elicia","family":"Penuel","sequence":"additional","affiliation":[{"name":"Genentech, Inc.  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanda","family":"Teodoro","sequence":"additional","affiliation":[{"name":"F. Hoffmann\u2010La Roche Ltd  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Tracy","sequence":"additional","affiliation":[{"name":"Genentech, Inc.  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denison","family":"Kuruvilla","sequence":"additional","affiliation":[{"name":"Genentech, Inc.  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Chen","sequence":"additional","affiliation":[{"name":"Genentech, Inc.  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Wiebking","sequence":"additional","affiliation":[{"name":"Genentech, Inc.  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Wei","sequence":"additional","affiliation":[{"name":"Genentech, Inc.  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1464-5494","authenticated-orcid":false,"given":"L. Elizabeth","family":"Budde","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center  Duarte California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15708"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01073"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15149"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00166-2"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01622-0"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021243"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02986-9"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2239"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00335-7"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-123933"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa4802"},{"key":"e_1_2_10_13_1","unstructured":"European Medicines Agency \u201cLunsumio: summary of product characteristics \u201dhttps:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/lunsumio\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_10_14_1","unstructured":"US Food and Drug Administration \u201cLunsumio: FDA prescribing information \u201dhttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761263s000lbl.pdf."},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025454"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-197897"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-2247"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024015274"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-135818"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157729"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.10.026"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/147176"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2024.2412869"},{"key":"e_1_2_10_26_1","unstructured":"European Medicines Agency \u201cOrdspono: summary of product characteristics \u201dhttps:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/ordspono\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-158413"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-158409"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004535"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2024000667"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw685"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-02882-1"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.70225","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.70225","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.70225","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T08:38:00Z","timestamp":1776242280000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.70225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1002\/ajh.70225"],"URL":"https:\/\/doi.org\/10.1002\/ajh.70225","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]},"assertion":[{"value":"2025-11-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}